Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study
Deba Prasad Dhibar, Navneet Arora, Arpit Kakkar, Neeraj Singla, Ritin Mohindra, Vikas Suri, Ashish Bhalla, Navneet Sharma, Mini P Singh, Ajay Prakash, Lakshmi Pvm, Bikash Medhi
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224
Many drugs have been tried for the treatment/prevention of COVID-19 with limited success. Direct household contacts of COVID-19 patients are at highest risk for SARS-CoV-2 infection. Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive. In this open-label, controlled clinical trial, asymptomatic individuals who had direct contact with laboratory-confirmed COVID-19 cases or had undertaken international travel in the last 2 weeks were offered HCQ prophylaxis and assigned to PEP ( n = 132) or control ( n = 185) group. The PEP group received HCQ 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks. Both groups undertook home quarantine for 2 weeks along with social distancing and personal hygiene. Over 4-week follow-up, 50/317 participants (15.8%) had new-onset COVID-19. The incidence of COVID-19 was significantly ( P = 0.033) lower in the PEP (14/132; 10.6%) compared to the control (36/185; 19.5%) group (total absolute risk reduction, -8.9% points). The NNT to prevent the occurrence of 1 COVID-19 case was 12. Overall relative risk was 0.59 (95% CI 0.33-1.05). Compliance was good. The most common adverse event was epigastric discomfort with burning sensation (three participants), with no serious adverse events. PEP with HCQ has the potential for the prevention of COVID-19 in at-risk individuals. Until definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals. Further randomised clinical trials with larger samples are required for better evaluation of HCQ as PEP for COVID-19 prevention.
References
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev,
doi:10.1002/14651858.MR000034.pub2Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem,
doi:10.1021/jm0601856Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2016638Catteau, Dauby, Montourcy, Bottieau, Hautekiet et al., Belgian Collaborative Group on COVID-19 Hospital Surveillance. Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.106144Chatterjee, Anand, Singh, Rasaily, Singh et al., Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19, Indian J Med Res,
doi:10.4103/ijmr.IJMR_2234_20Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Guan, Ni, Hu, Liang, Ou et al., China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med,
doi:10.1056/NEJMoa2002032Marmor, Kellner, Lai, Melles, Mieler, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision), Ophthalmology,
doi:10.1016/j.ophtha.2016.01.058Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101738Mygov, Government of India COVID-19 dashboard
Sarma, Kaur, Kumar, Mahendru, Avti et al., Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis, J Med Virol,
doi:10.1002/jmv.25898Sarma, Prajapat, Avti, Kaur, Kumar et al., Therapeutic options for the treatment of 2019-novel coronavirus: an evidence-based approach, J Pharmacol,
doi:10.4103/ijp.IJP_119_20Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237
